Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele
Young, Ross McD., Lawford, Bruce R., Barnes, Mark , Burton, Simon C. , Ritchie, Terry , Ward, Warren K., & Noble, Ernest P. (2004) Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele. The British Journal of Psychiatry, 185, pp. 147-151.
Background Hyperprolactinaemia induced by D2 dopamine receptor antagonist antipsychotic medication can result in significant health problems.
Aims To examine the role of DRD2 polymorphism on prolactin levels in patients treated with antipsychotic medication.
Method Antipsychotic drugs with different degrees of D2 receptor binding were given to 144 patients with schizophrenia. Serum prolactin levels were obtained and Taq1A DRD2 alleles were determined.
Results Prolactin levels increased across medication groups reflecting increasingly tight D2 receptor binding (clozapine, olanzapine, typical antipsychotics and risperidone). In the combined medication group, patients with the DRD2A1allele had 40% higher prolactin levels than patients without this allele. In patients treated with clozapine (the loosest D2 receptor binding agent), patients with the DRD2A1allele had prolactin levels twice those of patients without this allele.
Conclusions Patients with the DRD2A1 allele receiving antipsychotic medications had higher prolactin levels and were overrepresented among those with hyperprolactinaemia, suggesting greater functional D2 receptor binding in this group.
Impact and interest:
Citation countsare sourced monthly fromand citation databases.
These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.
Citations counts from theindexing service can be viewed at the linked Google Scholar™ search.
|Item Type:||Journal Article|
|Additional Information:||For more information, please refer to the journal’s website (see hypertext link) or contact the author. Author contact details: email@example.com|
|Subjects:||Australian and New Zealand Standard Research Classification > PSYCHOLOGY AND COGNITIVE SCIENCES (170000) > PSYCHOLOGY (170100) > Biological Psychology (Neuropsychology Psychopharmacology Physiological Psychology) (170101)|
Australian and New Zealand Standard Research Classification > MEDICAL AND HEALTH SCIENCES (110000) > NEUROSCIENCES (110900) > Central Nervous System (110903)
Australian and New Zealand Standard Research Classification > PSYCHOLOGY AND COGNITIVE SCIENCES (170000) > PSYCHOLOGY (170100) > Health Clinical and Counselling Psychology (170106)
|Divisions:||Current > Research Centres > Centre for Health Research|
Current > QUT Faculties and Divisions > Faculty of Health
Current > Institutes > Institute of Health and Biomedical Innovation
|Copyright Owner:||Copyright 2004 The Royal College of Psychiatrists|
|Deposited On:||02 Jul 2007|
|Last Modified:||29 Feb 2012 23:06|
Repository Staff Only: item control page